CR20220205A - INHIBICIÓN DE INTEGRINA a4ß7 HUMANA - Google Patents
INHIBICIÓN DE INTEGRINA a4ß7 HUMANAInfo
- Publication number
- CR20220205A CR20220205A CR20220205A CR20220205A CR20220205A CR 20220205 A CR20220205 A CR 20220205A CR 20220205 A CR20220205 A CR 20220205A CR 20220205 A CR20220205 A CR 20220205A CR 20220205 A CR20220205 A CR 20220205A
- Authority
- CR
- Costa Rica
- Prior art keywords
- inhibiting human
- human integrin
- sub
- integrin
- inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Radio Relay Systems (AREA)
- Air Conditioning Control Device (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962916062P | 2019-10-16 | 2019-10-16 | |
| PCT/US2020/055986 WO2021076890A1 (en) | 2019-10-16 | 2020-10-16 | INHIBITING HUMAN INTEGRIN α4β7 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220205A true CR20220205A (es) | 2022-07-22 |
Family
ID=73198501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220205A CR20220205A (es) | 2019-10-16 | 2020-10-16 | INHIBICIÓN DE INTEGRINA a4ß7 HUMANA |
Country Status (37)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3773573B1 (en) | 2018-04-12 | 2026-03-18 | Morphic Therapeutic, Inc. | Antagonists of human integrin (alpha4)(beta7) |
| FI3873884T3 (fi) | 2018-10-30 | 2025-02-24 | Gilead Sciences Inc | 3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa |
| WO2020232256A1 (en) | 2019-05-15 | 2020-11-19 | Chemocentryx, Inc. | Triaryl compounds for treatment of pd-l1 diseases |
| WO2021030438A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| TWI775182B (zh) | 2019-10-16 | 2022-08-21 | 美商莫菲克醫療股份有限公司 | 抑制人類整合素αβ |
| ES3064674T3 (en) | 2019-10-16 | 2026-04-28 | Chemocentryx Inc | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases |
| JP7736678B2 (ja) | 2019-10-16 | 2025-09-09 | ケモセントリックス，インコーポレイティド | Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド |
| US20250195485A1 (en) * | 2021-12-27 | 2025-06-19 | Xizang Haisco Pharmaceutical Co., Ltd. | Propionic acid derivative and medical use thereof |
| KR20250061759A (ko) | 2022-09-09 | 2025-05-08 | 시젱 하이스코 파마수티칼 씨오., 엘티디. | 프로피온산 유도체 및 이의 의약에서의 응용 |
| JP2025542171A (ja) | 2022-12-22 | 2025-12-25 | シンセラ， インコーポレイテッド | アルファ４ベータ７インテグリンアンタゴニスト及びその使用 |
| AU2024226489A1 (en) * | 2023-02-21 | 2025-10-02 | C4X Discovery Limited | Macrocyclic alpha4beta7 integrin inhibitors |
| CN121335980A (zh) | 2023-05-26 | 2026-01-13 | 阿达尔克斯制药有限公司 | Sod1调节组合物及其使用方法 |
| TW202508571A (zh) | 2023-07-28 | 2025-03-01 | 大陸商上海翰森生物醫藥科技有限公司 | 一種苯并含氮雜環類衍生物調節劑、其製備方法和應用 |
| WO2025026955A1 (en) * | 2023-07-28 | 2025-02-06 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| WO2025176107A1 (zh) * | 2024-02-20 | 2025-08-28 | 西藏海思科制药有限公司 | 一种吡啶酮衍生物及其在医药上的应用 |
| CN118702712B (zh) * | 2024-07-04 | 2025-11-11 | 安徽普利药业有限公司 | 一种n-(3-苯10硼酸)-l-天冬氨酸中间体制备方法 |
| WO2026018017A1 (en) * | 2024-07-19 | 2026-01-22 | C4X Discovery Limited | Therapeutic compounds |
| WO2026018016A1 (en) * | 2024-07-19 | 2026-01-22 | C4X Discovery Limited | Therapeutic compounds |
| CN119504796B (zh) * | 2024-11-20 | 2026-03-10 | 南通大学附属医院 | 一种具有抗肿瘤活性的化合物及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU681396B2 (en) | 1993-03-31 | 1997-08-28 | G.D. Searle & Co. | 1-amidinophenyl-pyrrolidones piperidinones azetinones as platelet aggregation inhibitors |
| DE4427979A1 (de) | 1993-11-15 | 1996-02-15 | Cassella Ag | Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung |
| US5849736A (en) | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| DE19622489A1 (de) | 1996-06-05 | 1997-12-11 | Hoechst Ag | Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters |
| CA2268270A1 (en) | 1996-10-11 | 1998-04-23 | Cor Therapeutics, Inc. | Heterocyclic derivatives as factor xa inhibitors |
| WO1998016547A1 (en) | 1996-10-11 | 1998-04-23 | Cor Therapeutics, Inc. | SELECTIVE FACTOR Xa INHIBITORS |
| DE19751251A1 (de) | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
| AU751950B2 (en) * | 1997-11-24 | 2002-09-05 | Merck & Co., Inc. | Substituted beta-alanine derivatives as cell adhesion inhibitors |
| US6645939B1 (en) | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
| MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| AU4584199A (en) | 1998-06-29 | 2000-01-17 | Du Pont Pharmaceuticals Company | Cyclic carbamates and isoxazolidines as iib/iiia antagonists |
| WO2000006169A1 (en) * | 1998-07-29 | 2000-02-10 | Merck & Co., Inc. | Integrin receptor antagonists |
| GB9826174D0 (en) * | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| RU2255933C9 (ru) | 1999-05-07 | 2005-11-20 | Тексэс Байотекнолоджи Копэрейшн | ПРОИЗВОДНЫЕ ПРОПИОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СЕЛЕКТИВНОГО ИНГИБИРОВАНИЯ СВЯЗЫВАНИЯ α4β1 ИНТЕГРИНА |
| US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| US6723711B2 (en) * | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| ES2288871T3 (es) | 1999-09-24 | 2008-02-01 | Genentech, Inc. | Derivados de tirosina. |
| DE10041423A1 (de) | 2000-08-23 | 2002-03-07 | Merck Patent Gmbh | Biphenylderivate |
| JP2004510708A (ja) * | 2000-08-30 | 2004-04-08 | ファルマシア・コーポレーション | ＧＥＭ置換αｖβ３インテグリンアンタゴニスト |
| DE10111876A1 (de) | 2001-03-10 | 2002-09-19 | Aventis Pharma Gmbh | Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe |
| DE10154280A1 (de) | 2001-11-05 | 2003-05-15 | Wilex Ag | Antagonisten für alpha¶4¶-Integrine |
| DK1485127T3 (da) | 2002-02-25 | 2011-10-03 | Elan Pharm Inc | Anvendelse af midler til behandling af inflammation |
| WO2006026759A2 (en) | 2004-09-03 | 2006-03-09 | Genentech, Inc. | Humanized anti-beta7 antagonists and uses therefor |
| EP1863940B1 (en) | 2005-03-03 | 2012-06-06 | Seedlings Life Science Ventures, LLC. | Method of risk management for patients undergoing natalizumab treatment |
| WO2006126529A1 (ja) | 2005-05-25 | 2006-11-30 | Shionogi & Co., Ltd. | ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体 |
| EA013080B1 (ru) | 2005-06-09 | 2010-02-26 | Юсб Фарма С.А. | 2,6-хинолинильные производные, способы их получения и их применение |
| US20070207141A1 (en) | 2006-02-28 | 2007-09-06 | Ivan Lieberburg | Methods of treating inflammatory and autoimmune diseases with natalizumab |
| US20100272680A1 (en) | 2009-02-09 | 2010-10-28 | Subramanian Baskaran | Piperidinyl Cyclic Amido Antiviral Agents |
| RU2016127812A (ru) | 2011-03-31 | 2018-12-06 | Дженентек, Инк. | Способы введения антагонистов интегрина бета7 |
| PL2903691T3 (pl) | 2012-10-05 | 2019-10-31 | Hoffmann La Roche | Sposoby diagnozowania i leczenia nieswoistego zapalenia jelit |
| WO2015148809A1 (en) | 2014-03-27 | 2015-10-01 | Genentech, Inc. | Methods for diagnosing and treating inflammatory bowel disease |
| WO2016011940A1 (zh) | 2014-07-25 | 2016-01-28 | 江苏恒瑞医药股份有限公司 | 氮茚-酰胺类衍生物、其制备方法及其在医药上的应用 |
| WO2016086147A1 (en) * | 2014-11-26 | 2016-06-02 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| HK1244229A1 (zh) | 2015-02-26 | 2018-08-03 | F. Hoffmann-La Roche Ag | 治疗CROHN病的整联蛋白β7拮抗剂和方法 |
| MX394210B (es) * | 2017-02-28 | 2025-03-04 | Morphic Therapeutic Inc | INHIBIDORES DE INTEGRINA AVß6. |
| US10875875B2 (en) * | 2017-04-26 | 2020-12-29 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
| US10246451B2 (en) | 2017-04-26 | 2019-04-02 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
| EP3773573B1 (en) * | 2018-04-12 | 2026-03-18 | Morphic Therapeutic, Inc. | Antagonists of human integrin (alpha4)(beta7) |
| JP7189368B2 (ja) * | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４ベータ７インテグリンの阻害のための化合物 |
| FI3873884T3 (fi) | 2018-10-30 | 2025-02-24 | Gilead Sciences Inc | 3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa |
| EP3873605B1 (en) | 2018-10-30 | 2024-10-23 | Gilead Sciences, Inc. | Compounds for inhibition of alpha4beta7 integrin |
| ES3013256T3 (en) | 2018-10-30 | 2025-04-11 | Gilead Sciences Inc | Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| TWI775182B (zh) | 2019-10-16 | 2022-08-21 | 美商莫菲克醫療股份有限公司 | 抑制人類整合素αβ |
-
2020
- 2020-10-16 TW TW109136036A patent/TWI775182B/zh active
- 2020-10-16 HU HUE20875989A patent/HUE071814T2/hu unknown
- 2020-10-16 ES ES20875989T patent/ES3035561T3/es active Active
- 2020-10-16 CA CA3154269A patent/CA3154269A1/en active Pending
- 2020-10-16 PT PT208759894T patent/PT4045039T/pt unknown
- 2020-10-16 MD MDE20220933T patent/MD4045039T2/ro unknown
- 2020-10-16 MA MA57399A patent/MA57399B1/fr unknown
- 2020-10-16 DK DK20875989.4T patent/DK4045039T3/da active
- 2020-10-16 JP JP2022509595A patent/JP7437490B2/ja active Active
- 2020-10-16 HR HRP20250749TT patent/HRP20250749T1/hr unknown
- 2020-10-16 RS RS20250645A patent/RS66976B1/sr unknown
- 2020-10-16 UY UY0001038926A patent/UY38926A/es unknown
- 2020-10-16 IL IL319053A patent/IL319053A/en unknown
- 2020-10-16 PY PY202002065718A patent/PY2065718A/es unknown
- 2020-10-16 US US17/072,797 patent/US11104661B1/en active Active
- 2020-10-16 FI FIEP20875989.4T patent/FI4045039T3/fi active
- 2020-10-16 AR ARP200102870A patent/AR120244A1/es unknown
- 2020-10-16 MX MX2022004406A patent/MX2022004406A/es unknown
- 2020-10-16 PH PH1/2022/550886A patent/PH12022550886A1/en unknown
- 2020-10-16 CN CN202411308053.XA patent/CN119192137A/zh active Pending
- 2020-10-16 TW TW111127993A patent/TWI802477B/zh active
- 2020-10-16 TW TW112116098A patent/TWI857592B/zh active
- 2020-10-16 US US17/769,003 patent/US20240174632A1/en active Pending
- 2020-10-16 CN CN202080088450.4A patent/CN115087444B/zh active Active
- 2020-10-16 WO PCT/US2020/056001 patent/WO2021076902A1/en not_active Ceased
- 2020-10-16 PE PE2022000633A patent/PE20221829A1/es unknown
- 2020-10-16 CR CR20220205A patent/CR20220205A/es unknown
- 2020-10-16 BR BR112022007284A patent/BR112022007284A2/pt unknown
- 2020-10-16 SI SI202030622T patent/SI4045039T1/sl unknown
- 2020-10-16 AU AU2020366435A patent/AU2020366435A1/en active Pending
- 2020-10-16 LT LTEPPCT/US2020/055986T patent/LT4045039T/lt unknown
- 2020-10-16 PL PL20875989.4T patent/PL4045039T3/pl unknown
- 2020-10-16 EP EP20875989.4A patent/EP4045039B1/en active Active
- 2020-10-16 UA UAA202201185A patent/UA130059C2/uk unknown
- 2020-10-16 EP EP25157767.2A patent/EP4559525A3/en active Pending
- 2020-10-16 CU CU2022000027A patent/CU20220027A7/es unknown
- 2020-10-16 JP JP2022523102A patent/JP7437495B2/ja active Active
- 2020-10-16 WO PCT/US2020/055986 patent/WO2021076890A1/en not_active Ceased
- 2020-10-16 TW TW113132607A patent/TWI900200B/zh active
- 2020-10-16 KR KR1020227015040A patent/KR20220102669A/ko active Pending
-
2021
- 2021-07-16 US US17/378,282 patent/US11370773B1/en active Active
- 2021-10-15 WO PCT/US2021/055196 patent/WO2022081983A1/en not_active Ceased
- 2021-10-15 EP EP21881178.4A patent/EP4228634A4/en active Pending
- 2021-10-15 TW TW113110859A patent/TWI888065B/zh active
- 2021-10-15 TW TW111149835A patent/TWI840047B/zh active
- 2021-10-15 CN CN202180083775.8A patent/CN116783161B/zh active Active
- 2021-10-15 KR KR1020237015039A patent/KR20230088376A/ko active Pending
- 2021-10-15 AU AU2021361031A patent/AU2021361031A1/en active Pending
- 2021-10-15 TW TW110138309A patent/TWI791304B/zh active
- 2021-10-15 JP JP2021576053A patent/JP7209116B2/ja active Active
-
2022
- 2022-04-05 ZA ZA2022/03872A patent/ZA202203872B/en unknown
- 2022-04-13 DO DO2022000081A patent/DOP2022000081A/es unknown
- 2022-04-14 CL CL2022000959A patent/CL2022000959A1/es unknown
- 2022-04-14 IL IL292296A patent/IL292296B2/en unknown
- 2022-05-02 CO CONC2022/0005759A patent/CO2022005759A2/es unknown
- 2022-05-16 EC ECSENADI202238978A patent/ECSP22038978A/es unknown
-
2023
- 2023-01-06 JP JP2023000761A patent/JP7500785B2/ja active Active
- 2023-03-30 ZA ZA2023/03992A patent/ZA202303992B/en unknown
-
2024
- 2024-02-09 JP JP2024018866A patent/JP7702004B2/ja active Active
- 2024-02-09 JP JP2024018765A patent/JP7717202B2/ja active Active
- 2024-06-05 JP JP2024091304A patent/JP2024116230A/ja active Pending
-
2025
- 2025-02-19 DO DO2025000034A patent/DOP2025000034A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220205A (es) | INHIBICIÓN DE INTEGRINA a4ß7 HUMANA | |
| MX2022009056A (es) | Inhibidores de integrina ?v?6. | |
| PH12021550187A1 (en) | Pyrrolopyrimidine itk inhibitors | |
| JOP20210244A1 (ar) | مركبات وتركيبات وطرائق لمعالجة الأمراض | |
| PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| PH12022550509A1 (en) | Anti-cd73 antibodies | |
| MX2017009571A (es) | Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer. | |
| MY203427A (en) | 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm) | |
| MX2019000536A (es) | Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1. | |
| PH12023552830A1 (en) | Compositions and methods for inhibiting ketohexokinase | |
| PH12017501095A1 (en) | Piperidine derivatives as hdac1/2 inhibitors | |
| MX2022004373A (es) | Celulas madre modificadas y metodos de uso de las mismas. | |
| PH12020550255A1 (en) | Treatment of smc mediated disease | |
| MX2024008100A (es) | Lactamas funcionalizadas novedosas como moduladores del receptor 7 de 5-hidroxitriptamina y su metodo de uso. | |
| MX2023005591A (es) | Metodos de tratamiento de enfermedades y trastornos. | |
| MX2021006682A (es) | Inhibidores de descarboxilasa para el tratamiento de la enfermedad de parkinson. | |
| MX2026002367A (es) | Composiciones de copolimero de bloque sensibles al ph, micelas, y metodos de uso | |
| WO2020068950A8 (en) | Hdac1,2 inhibitors | |
| MX2020011453A (es) | Combinaciones para tratar el cancer. | |
| WO2018158542A8 (fr) | Cellules souches mesenchymateuses issues de la gelée de wharton pour le traitement du sepsis | |
| ZA202211253B (en) | Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases | |
| PH12020550594A1 (en) | New alcoxyamino derivatives for treating pain and pain related conditions | |
| SA522432069B1 (ar) | Nrp1a أجسام مضادة لـ واستخداماتها لعلاج العين أو أمراض العين | |
| EP4272830A3 (en) | Tissue organoids | |
| PH12020500290A1 (en) | Pesticidal composition and a process for its preparation |